ADC Bio wins National Best for Innovation Award

ADC Bio wins National Best for Innovation Award

ADC Bio has won the national 2014 Best for Innovation Award in the British Private Equity and Venture Capital Association’s (BVCA) Management Team Awards.

As announced last month (May) the company had already taken the Wales Regional Award – and has now beaten seven other UK regions to the national prize in the Innovation category.

The Awards recognise the success of the management team in driving innovation through new process technology that helps drug makers to contain complexity and cost in the latest generation of anti-cancer drugs. Accepting the Awards at the BVCA dinner on 18 June, ADC Bio CEO Charlie Johnson commented: “This recognises both three years of technology development work by the team at our Wales facility and the exciting story of antibody drug conjugates (ADCs) in accelerating the fight against cancer.”

Over 150 UK companies were nominated for the 2014 BVCA Management Team Awards, given in each of seven categories. Nominations were subject to an intense due diligence programme and in-depth interviews by the judging panel.

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.